Ian Michael Estepan - 16 Dec 2025 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role: Chief Operating Officer
Signature: /s/ Cristin L. Rothfuss, as Attorney-in-Fact for Ian Michael Estepan
Issuer symbol: SRPT
Transactions as of: 16 Dec 2025
Net transactions value: -$294,202
Form type: 4
Filing time: 18 Dec 2025, 20:05:03 UTC
Previous filing: 05 Sep 2025
Next filing: 27 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Estepan Ian Michael	Chief Operating Officer	215 FIRST STREET, SUITE 415, CAMBRIDGE	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Ian Michael Estepan	18 Dec 2025	0001836254

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SRPT	Common Stock	Sale	$294,202	-13,187	-6.4%	$22.31	193,300	16 Dec 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.35 to 22.29, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Content

Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.35 to 22.29, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.